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ABSTRACT
This review presents an introduction to Raman scattering
and describes the various Raman spectroscopy, Raman mi-
croscopy, and chemical imaging techniques that have dem-
onstrated utility in biocolloidal self-assemblies, pharmaceutical
drug delivery systems, and pulmonary research applications.
Recent Raman applications to pharmaceutical aerosols in
the context of pulmonary inhalation aerosol delivery are dis-
cussed. The “molecular fingerprint” insight that Raman ap-
plications provide includes molecular structure, drug-carrier/
excipient interactions, intramolecular and intermolecular
bonding, surface structure, surface and interfacial interac-
tions, and the functional groups involved therein. The mo-
lecular, surface, and interfacial properties that Raman
characterization can provide are particularly important in
respirable pharmaceutical powders, as these particles possess
a higher surface-area-to-volume ratio; hence, understanding
the nature of these solid surfaces can enable their manipu-
lation and tailoring for functionality at the nanometer level
for targeted pulmonary delivery and deposition. Moreover,
Raman mapping of aerosols at the micro- and nanometer
level of resolution is achievable with new, sophisticated,
commercially available Raman microspectroscopy techni-
ques. This noninvasive, highly versatile analytical and im-
aging technique exhibits vast potential for in vitro and in vivo
molecular investigations of pulmonary aerosol delivery, lung
deposition, and pulmonary cellular drug uptake and disposi-
tion in unfixed living pulmonary cells.
KEYWORDS: Spectroscopy, microscopy, imaging, molec-
ular, interfacial, lung, mappingR
INTRODUCTION—THE RAMAN EFFECT
Elastic scattering of photons (Rayleigh scattering) from in-
coming light occurs with the same frequency (energy) and
hence wavelength as the incident photons, as depicted in
Figure 1a. The Raman effect was discovered by the Indian
physicist Sir Chandrasekhara Venkata Raman, who was
awarded the Nobel Prize in Physics in 1930 for his seminal
discoveries on the “molecular diffraction of light” in liquids
and the “diffusion of gases.”1-3 The Raman effect is the pro-
cess whereby inelastic scatter of outgoing photons occurs,
which is typically a small fraction of scattered photons at a
different and higher optical frequency from the incident pho-
tonic frequency. Raman shift in wave numbers (cm–1) is de-
fined as the difference between the incident light, λincident,
and the Raman scattering of photons, λscattered. In other words,
the vibrational energy of the scattering molecule is the en-
ergy difference between the incident and Raman-scattered
photons. A typical Raman spectrum consists of a plot of the
scattered light as a function of the energy difference. Figure 1
illustrates the scattering effects that give rise to the Raman
effect, which occurs when the incident photon interacts with
the electric dipole of the molecule, pertubating the molecule’s
electrical field. This is a quantum mechanical phenomenon,
whereby the scattering can be described as a vibrational en-
ergy change resulting from an excitation to a lower energy
state rather than a real electronic transition. The scattered
photon will have a longer wavelength (lower energy) than
the incoming photon (exciting photon), resulting in a Stokes
Raman scattering, as depicted in Figure 1b. The Stokes-
shifted Raman spectrum (Figure 1b) is stronger than the
anti-Stokes-shifted spectrum (Figure 1c), and both contain
the same frequency information. The ratio of both spectra
can provide information on temperature.
Vibrational energy and bond-stretching frequency are de-
termined by several molecular properties, including atom
types, atomic mass, molecular geometry, hydrogen bonding,
and bond order (single bond vs double bond vs triple bond).
It is important to recognize that Raman scattering measures
molecular polarizability (the extent to which an electronic
cloud can be distorted), as molecular vibrations can affect po-
larizability, providing useful information on molecular dipoles.
Hence, both intramolecular and intermolecular vibrations are
Received: November 30, 20 6; Final R vision Received: June 9, 2007; Accept d: June 11, 2007; Published: November 30, 2007
AAPS PharmSciTech 2007; 8 (4) Article 99 (http://www.aapspharmscitech.org).
E1
Corresponding Author: Heidi M. Mansour, University of
North Carolina at Chapel Hill, School of Pharmacy,
Division of Molecular Pharmaceutics, Campus Box #7360,
311 Pharmacy Lane, 1311 Kerr Hall, Dispersed Systems
Laboratory, Chapel Hill, NC 27599-7360. Tel: (919) 966-
0484; Fax: (919) 966-0197; E-mail: hmmansour@unc.edu
Raman-active. The Raman-active vibration selection rule states
that there must be a change in polarizability accompanying
a vibration. In other words, strong Raman scattering occurs
with a larger change in polarizability of distributed electron
clouds, as found in a carbon-carbon double bond where the
π-electron cloud is easily distorted because bond stretching
and/or bending causes a significant change in the electron
cloud density and induced-dipole moment. Hence, aroma-
ticity is associated with strong symmetric vibration and a
strong Raman band. Strong Raman scatters have symmetrical
vibrations and include phenyl moieties and other aromatic
moieties,4 sulfide bonds, and carbon-carbon single and dou-
ble bonds, which are all common structural characteristics
of many pharmaceutical molecules. In contrast, the O-H bond
is inherently highly polar because of the uneven distribution
of the electron cloud favoring the oxygen atom; hence, polar-
izability is low and so is the Raman scattering. This is due to
the fact that a highly polar moiety, such as the O-H bond,
has a weak vibration and low Raman band, which is ideal
for aqueous systems.
It is noted that infrared (IR) spectroscopy is also commonly
used in molecular characterization of pharmaceutical mate-
rials, as it is complementary to Raman spectroscopy; how-
ever, sample preparation is required. Another benefit of
Raman is that there tends to be less spectral overlap with
common pharmaceutical excipients.5 Additionally, phar-
maceutical drug product containers (eg, glass and plastic)
absorb mid-IR light due mainly to C-H vibrations, so non-
invasive drug product identification and on-line process (in
situ) monitoring is not possible with IR, as it is with Raman
spectroscopy (to be discussed below).6 Unlike Raman spec-
troscopy (symmetric vibration), IR requires a dipole moment
change (ie, asymmetric vibration). Accordingly, weak Raman
scatters tend to be strong IR absorbers and include bond
vibrations present in polar moieties, such as carbonyl and
hydrogen-bonded hydroxyl groups, since they display asym-
metric (IR) rather than symmetric (Raman) vibrations. The
various types of Raman spectroscopy and their applications
are summarized in Table 1.
Several excellent reviews7-9 discuss in detail the Raman ef-
fect, the various types of Raman spectroscopy, Raman band
frequencies,10,11 and the many applications of Raman spec-
troscopy in chemistry, biology, material science, and medi-
cine. Raman spectroscopy can provide important information
on molecular composition, structure, conformation, the de-
gree of order and/or disorder, phases and phase transitions,
Figure 1. Principles of Raman scattering: (A) Rayleigh scattering;
(B) Stokes Raman scattering; and (C) anti-Stokes Raman
scattering.
Table 1. Types of Raman Systems and Their Applications in the
Characterization and Analysis of Pharmaceutical, Biocolloidal,
and Aerosol Systems
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inter- and intramolecular interactions, hydrogen bonding, poly-
morphs, hydrates, anhydrates, molecular conformation, and
polymer chain conformation. The purpose of this review is to
highlight the main types of Raman spectroscopy and Raman
microscopy (chemical imaging) techniques that have been
successfully employed in the pharmaceutical sciences, with
an emphasis on biocolloidal self-assemblies, nonaerosol drug
delivery systems, and pulmonary inhalation aerosols. Addi-
tionally, this review will describe in detail the reports of Ra-
man applications in pulmonary medicine and pharmaceutical
inhalation aerosols demonstrating the potential for routine
application of this powerful analytical and imaging technique
in the molecular and surface characterization of inhalation
aerosol delivery systems.
TYPES OF RAMAN SPECTROSCOPY
Fourier Transform Raman Spectroscopy
Fourier transform Raman (FT-Raman), the Raman method
commonly used in pharmaceutical systems, prevents fluores-
cent background by using a longer wavelength in the near-IR
region (typically 1064 nm).12 Its success in routine phar-
maceutical analysis can be attributed to its specificity (molec-
ular fingerprint), reliability, efficiency, and cost-effectiveness
as a quantitative method compared with high-pressure liquid
chromatography, which always requires sample pretreatment
and the use of solvents. Furthermore, it is a nondestructive
and noninvasive biochemical analytical method.
Resonance-Enhanced Raman Spectroscopy
Resonance-enhanced Raman spectroscopy (RERS) occurs
if the wavelength of the incoming exciting laser is near or
within the electronic energy spectrum of the sample molec-
ule, causing a resonance enhancement in the intensity of mo-
lecular vibrations. This is in contrast to conventional Raman
spectroscopy, where, according to scattering theory, the wave-
length of the incoming exciting laser is far below the first
electronic transitions. This Raman method13 has also been
used extensively in pharmaceutical systems. Accuracy, preci-
sion, and enhanced sensitivity are all advantages in RERS.
Surface-Enhanced Raman Spectroscopy
In an effort to overcome the inherently weak Raman signals
in conventional Raman methods and the ever-present prob-
lem of fluorescence of many API materials, surface-enhanced
Raman spectroscopy (SERS) provides stronger Raman sig-
nals by taking advantage of electromagnetic enhancement
and charge-transfer states. SERS14 is quite useful in the study
of biocolloidal dispersions (Figure 2), biomonomolecular
layers (monolayers/nanolayers) of materials and their surfa-
ces, including biomimetic models, biopolymers, inclusion
complexes, living cells, nanoparticles, and pharmaceutical
materials. Unique applications of SERS include colloidal
dispersions, molecular self-assemblies, DNA/RNA mono-
nucleotides,15 oligonucleotides, nanoparticles, surfaces, mono-
layers, chemical sensing, biochemical analysis, biomedical
diagnostics,16 rheology and gelation of hydrogels,17 biopol-
ymer surface orientation, membrane transport processes,18
colloidal nanostructures,19 bacterial cells, single living cell
uptake of nanoparticles,20 and interfacial molecular interac-
tions. Surface-enhanced hyper-Raman scattering incorporates
2-photon excitation with SERS, enabling the investigation
of nanoparticles with single biological cells.21
RAMAN CHEMICAL IMAGING OF BIOCOLLOIDAL
SELF-ASSEMBLIES AND NONAEROSOL
PHARMACEUTICAL DELIVERY SYSTEMS
In general pharmaceutical analysis, Raman spectroscopy22 is
a real-time, noncontact, and noninvasive analytical technique
in the chemical analysis, characterization, and quantification
of various structures, metastable phases, molecular interac-
tions, and reactivity in pharmaceutical solid dosage forms
and powders5,8,9,12,23-26 with minimal sample preparation.
Figure 2. Aqueous dispersions of biocolloidal self-assemblies
studied by Raman spectroscopy: (A) phospholipid monomolecular
layers (nanolayers) at the air-water interface; (B) micelles;
(C) liposomes; (C) DNA; and (E) helical protein.
AAPS PharmSciTech 2007; 8 (4) Article 99 (http://www.aapspharmscitech.org).
E3
Raman chemical imaging (Figure 3) using Raman micro-
scopy provides nondestructive, noninvasive molecular imag-
ing capability without the use of fluorescent dyes or external
markers. These advantages have vastly expanded Raman ca-
pabilities to biomacromolecular self-assemblies (eg, nucleic
acid complexes and viruses),27,28 shown in Figure 2, and
biological media (eg, cell-based assays), with considerable
application to in vitro and in vivo pharmaceutical science
research.24,29 Incorporating an optical microscope and motor-
ized stage into the Raman instrument for spectroscopic chem-
ical imaging by obtaining spectra for a defined 2-dimensional
area with a resolution down to 1 μm12 has further expanded
Raman spectroscopy’s utility in various structural and mo-
lecular investigations. These direct and quantitative Raman
chemical imaging (Figure 3) and mapping (Figure 4) inves-
tigations include biomaterial nanotubes (providing a spatial
resolution of ~25 nm),30 drug-polymer-controlled drug deliv-
ery systems,31,32 solid-state polymorphic transformations,33-37
and drug disposition research.24,38-42 The combination of
scanning electron microscopy (SEM) and Raman spectro-
scopy has been applied in single-crystal hydration studies of
carbamazepine, in the absence and presence of excipients,
where it was demonstrated that defect structures were of
greater importance in the initiation of the hydration process
than the crystal face.43
Unlabeled and unfixed single living cells and organelles can
be molecularly examined rapidly, noninvasively, and non-
destructively by Raman chemical imaging. This novel tech-
nique has great potential in medical applications (ex vivo
and in vivo),44 tissue engineering, and drug discovery by
virtue of its noninvasive, nondestructive, and rapid molecu-
lar fingerprinting of the effects of pharmaceuticals on single
living cells at various stages of the cell cycle, with detailed
nanometer spatial resolution.45 Raman chemical imaging has
been used in cell biology,46,47 dipalmitoylphosphatidylcho-
line (DPPC)/cholesterol vesicle bilayer phase behavior,48 dif-
ferential tissue histopathology and chemical composition
variation for cancer detection and degree of cancer progres-
sion in different tissue types,47,49-53 and identification of and
differentiation between multidrug-resistant cancer cells.54
Recently, laser scanning confocal microscopy imaging and
Raman spectroscopy have been demonstrated to be very use-
ful in noninvasive mapping (Figure 4) of chemical properties
with high-resolution images, including 3-dimensional (3-D)
views. The advantages of a confocal optical setup are (1) re-
duced unwanted background signals, (2) enhanced contrast,
(3) stacking, and (4) depth information via 3-D imaging re-
sulting in high spatial and temporal resolution. Differences in
chemical composition not seen in the optical image become
directly apparent in the Raman image. In addition, this non-
destructive imaging of chemical properties and phases is per-
formed without extensive or special sample preparation. In
sophisticated setups, complete spectra can be obtained for
each image pixel, and, conversely, images can be obtained on
certain parts of interest in the Raman spectrum. Confocal Ra-
man microspectroscopy55 has been reported to have great po-
tential for efficiency in assessing and quantifying the physical
state of a drug, physicochemical stability of the formulation,
content, and homogeneity of drug distribution in a polymer
formulation matrix.56 Additionally, confocal Raman micro-
spectroscopy has been employed in protein crystallization,57
molecular imaging of the effects of penetration enhancers
and drugs on in vivo human stratum corneum,58-60 and in vivo
human skin analysis.61 With an elegant combination of con-
focal Raman spectroscopy with laser tweezers (ie, optical
trapping to isolate single cells in a more natural state, as
opposed to adsorption onto the surface of a solid substrate,
Figure 3. Various types of Raman microspectroscopic chemical
imaging.
Figure 4. Schematic of Raman mapping.
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which is known to disturb the natural state), rapid identifi-
cation of single live cells (bacterial cells and fungal spores)
and organelles can be accomplished from every angle.62-64
Additionally, efforts are being made in expanding laser tweezer
confocal Raman molecular application to single live cell can-
cer screening with a 98.3% cancer detection sensitivity based
on intrinsic characteristic biomolecular differences (as op-
posed to physical attributes, eg, surface phenotype) in single
live transformed lymphocytes and normal human lympho-
cytes.65 Laser tweezer Raman spectroscopy has been used in
investigating the activation of individual T cells66 and the
dynamic real-time effects of alcohol on a single living red
blood cell.67
Raman microscopy 3-D profiling has been performed with
atomic force microscopy (AFM) phase imaging with con-
focal Raman microscopy to successfully identify and ana-
lyze, at the nanometer level, the distribution of amorphous
regions on the surface of semicrystalline solid pharmaceut-
ical excipients.68 It was shown that Raman spectroscopy
can complement AFM and can provide micrometer-level
information (with lateral spatial resolution on the order of
1-2 μm)69 on the depth of the surface amorphous domains,
particularly as it applies to semicrystalline particles, in addi-
tion to characterizing bonding interactions and quantifying
amorphicity/degree of crystallinity content. In addition, con-
focal Raman microimaging of pharmaceutical coatings in con-
junction with AFM analysis has been reported in identifying
the chemical composition of small areas of the coating.70
Disadvantages of classical Raman spectroscopy, in the con-
text of pharmaceutical applications, are fluorescence in the
sample interfering with Raman scatter detectability and the
inherently weak Raman scattering process, resulting in low
sensitivity and the need for sensitive detectors and intense
laser excitation sources.23 SERS16,23,71 overcomes these lim-
itations by providing high sensitivity and hence is a powerful
analytical technique for biocolloidal systems, antibiotic drug
adsorption,72 precise drug detection and quantification in bod-
ily fluids,73 and antiretroviral74,75 and antitubercle bacillus
drug76 molecular conformational investigations. Using a com-
bination of micro-Raman and SERS, the recognition process
of drugs with large biomolecules (eg, albumin) through the
use of colloidal nanoparticles was reported through investiga-
tion of the binding properties of the drugs with albumin.77
Surface-enhanced Raman microscopy has been successfully
used in imaging of live cells,78 including individual human
lymphocyte cells.79 SERS-confocal microscopy has been used
in chemical imaging of cellular proteins, including enzymes,
cellular proteins, and receptors in single cells.80 Surface-
enhanced micro-Raman spectroscopy in model diagnostic
systems incorporating microfluidics81 showed potentially pro-
mising application in pharmaceutical research and clinical
chemistry. Bacterial discrimination82 via SEM-SERS, and
viral detection in immunoassays83 and DNA nanoimaging84
via SERS-AFM, have been recently reported. A novel chemi-
cal nanoimaging technique combines SERS with AFM
(tapping mode) to provide highly detailed spectra and high-
resolution chemical imaging of biological materials, includ-
ing bacterial cells and DNA bases.85
RAMAN APPLICATIONS IN PULMONARY SYSTEMS
AND PHARMACEUTICAL INHALATION AEROSOLS
Atmospheric polluting particulate matter, consisting of poly-
aromatic hydrocarbons and particulate soot, and its relation-
ship to pulmonary diseases (ie, pneumonia, asthma, chronic
obstructive pulmonary disease, and lung cancer), global cli-
mate change, and oceanic warming have been the subject of
intense research for many decades. This is especially true
in recent years, when “molecular fingerprint” characteriza-
tion tools, such as Raman chemical imaging and mapping
(Figures 3 and 4, respectively), have revealed demonstrated
utility in atmospheric aerosol and bioaerosol research. Much
attention has been given to bioaerosols and their relationship
to various types of pulmonary allergic and infectious diseases.
Additionally, the topic of infectious bioaerosols is gaining
particular attention in the context of biodefense and global
public health. Based on the successes of Raman spectroscopy
in atmospheric and bioaerosol research, Raman applications
for the respiratory system and pharmaceutical inhalation ae-
rosols are being increasingly reported. As will be revealed in
the following discussion, Raman spectroscopy has great pro-
mise for vast and powerful application in therapeutic inhala-
tion aerosols, pulmonary histopathology, pulmonary infectious
diseases, pulmonary immunology, lung surfactant biophysics
and interfacial phenomena, and respiratory molecular biology.
Raman Spectroscopy in Atmospheric Aerosols and
Aerosol Particulate Reactions
Raman spectroscopy has been traditionally employed in in-
vestigating and characterizing single aerosol particles,86,87
atmospheric aerosol particles,88 and microparticle multicom-
ponent aerosols.89 Raman spectroscopy has been applied to
successful in situ measurement of the chemical compositions
of monodisperse and polydisperse aerosols in the micrometer
size range with a low signal-to-noise ratio.90 In situ chemical
analysis of ambient uncharged atmospheric aerosol particles
with diameters 9 1 μm was captured using an electrodynamic
balance and levitated while Raman spectroscopy with a charge-
coupled device (CCD) detector was successfully employed to
identify chemical substances in the aerosol particles.91 Raman
chemical imaging using SEM and confocal laser scanning mi-
croscopy (CLSM) has also been used in the mapping of fine
particulate atmospheric aerosols,92,93 mass and heat transfer
effects on evaporating aerosol droplets,94,95 aerosol water
droplet growth,96,97 single aerosol droplet physical and chem-
ical dynamics,98 gas-aerosol chemical reactions involving
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water vapor and greenhouse gases,99-103 aerosol chemical re-
actions in the synthesis of polymeric microspheres,104 and in-
terfacial hydrogen bonding in water aerosols.105 As seen with
nonaerosol systems, enhanced Raman scattering signal was
observed in aerosol chemicals analyzed by resonance Raman
spectroscopy.106 Raman microspectroscopy (Figure 3) has
enabled the imaging and molecular fingerprinting (Figure 4)
of hydrocarbon-water mixing during multicomponent aerosol
particle formation.107
Raman Investigations of Bioaerosols
Raman characterization of bioaerosols, such as pollen, vi-
ruses, and bacteria, that are regularly inhaled and can cause
and exacerbate pulmonary diseases has been reported.108-110
Aerosolized aqueous suspensions of bioaerosols containing
Escherichia coli, Pseudomonas aeruginosa, and Salmonella
typhimurium have been examined using SERS.111 Infectious
bioaerosolized pathogens acquired by the pulmonary route
have been the subject of much interest in global public health
and biodefense. Bioaerosols consisting of aerosolized nano-
colloidal suspensions of pollen,112E coli,112Bacillus anthracis
(anthrax),113Francisella tularensis (tularemia),113 and Bacillus
subtilis (anthrax spores)114 have been successfully detected
at low levels and molecularly characterized by Raman chem-
ical imaging and SERS.
Raman Studies of the Respiratory System
As mentioned previously, antimicrobial drugs used in the
treatment of the pulmonary infection tuberculosis have been
investigated using SERS.76 Additionally, the various parts
of the pulmonary system have been investigated using Ra-
man spectroscopy. The interfacial properties and molecular
interactions (ie, electrostatic, hydrophobic, hydrogen bond-
ing, and van der Waals) of human lung surfactant models
containing DPPC, and/or palmitoyloleoylphosphatidylglycerol
(POPG), with synthetic cationic hydrophobic heteropolypep-
tide surfactant derivatives of human surfactant protein SP-B
were deciphered by quantitative Raman interaction parame-
ters reported by Vincent et al.115 Additionally, they found
using model human lung surfactant systems of DPPC mixed
with DPPG (dipalmitoylphosphatidylglycerol) that specific
lipid-heteropolypeptide interactions result in a dynamic bi-
layer microdomain heterogeneity116 that is necessary for the
normal mechanics of pulmonary respiration.
Various types of immortal and mortal pulmonary cell lines
have been employed in many in vitro models of pulmonary
transport and absorption studies of pulmonary aerosol and
particulate uptake.117
In an effort to apply powerful spectroscopic and chemical
imaging techniques in the study and molecular character-
ization of the pulmonary system at the cellular and sub-
cellular levels, in very recent years, Raman spectroscopy has
just begun to demonstrate its unique and vast utility in non-
invasive and nondestructive in vitro and in vivo pulmonary
cell and subcellular applications. The molecular structure of
cellular components of single lung fibroblast cells (without
labeling) under stress followed by apoptosis has been ex-
amined by Raman mapping.118 In an unlabeled single cell
undergoing apoptosis, it was demonstrated that the Raman
band intensity of the nucleic acids present in the nucleus
and cytoplasm decreased as the number of cell surface blis-
ters (having higher nucleic acid content) increased, which
was indicative of nucleus degradation.118 It was reported
by Kaminaka et al119,120 that Raman spectroscopy of human
lung tissue (normal and cancerous) demonstrated that 2 strong
vibrational bands at 1666 and 1448 cm–1, representing col-
lagen, increased in lung tissues upon lung cancer progres-
sion (as noted in other cancerous tissue systems) and hence
can be used as a Raman marker in diagnosis.
The molecular composition and histological evaluation of
normal human bronchial tissue was characterized in situ by
Raman mapping, as reported by Koljenovic et al,121 who
sought to have a biochemical and molecular understanding
of lung cancer. They found that the spectra of bronchial
mucus, which has relatively high quantities of triolein, were
dominated by strong lipid signals, and strong collagen and
glycosaminoglycan signals were associated with cartilage.
Relatively lower lipid and higher DNA signals were asso-
ciated with the basal side of the bronchial epithelium.
It was shown that formalin, which preserves normal and
malignant human bronchial tissues, does significantly and
adversely affect the Raman spectra of these tissues through
the introduction of artifacts; and hence, when using fixed
tissue, thorough rinsing in phosphate-buffered saline may
assist in obtaining more meaningful Raman spectra.122,123
The authors found that formalin fixation did not affect the
major Raman signals for lipids and proteins, but the Raman
intensities did decrease upon formalin fixation compared with
fresh unfixed human bronchial tissue. This decrease was sug-
gested to be associated with the effect of formalin on the
bronchial lipid self-assembly. In tumor tissue, the same trend
was reported, particularly for the porphyrin (hemoglobin from
the blood) and water Raman bands, as it related to the state of
hydration of the lung tissue samples. For Raman lung tissue
studies for molecular characterization of normal and lung
cancer states, the authors recommended using fresh tissue
rather than formalin-fixed tissue or in vivo Raman analysis.
In one study using Raman spectroscopy on fresh (unfixed
and never frozen) lung tissue using normal and malig-
nant lung tissue it was found that the normalized Raman
phospholipid band intensities decreased and the amide I
and amide III vibrational bands increased in lung cancer
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development123,124 as the protein content increased and
protein conformational changes occurred, accompanied by
increased nucleic acid content. The authors suggest that this
can be attributed to the very unique organ structure of the
lungs: compared with other organs, the lungs are less dense,
with relatively small amounts of protein, and the density
increases as the protein content increases (ie, amide I band)
during disease progression.
Raman Investigations of Pharmaceutical
Inhalation Aerosols
Raman spectroscopy and chemical imaging is beginning to
find increasing application in the molecular characteriza-
tion of pharmaceutical aerosols125-127 for pulmonary deliv-
ery, and in particular, dry powder inhalation aerosol delivery
systems.117,128,129 Depicted in Figures 5 and 6, respec-
tively, are the chemical structures (ChemDraw Ultra 10.0,
ChemOffice 2006, Cambridgesoft, Cambridge, MA) and
molecular modeling (Chem 3DPro 10.0, ChemOffice 2006,
Cambridgesoft) of the pulmonary drugs that have been char-
acterized by Raman spectroscopy. Similarly, Figure 7 shows
the chemical structures and molecular modeling of pulmonary
inhalation aerosol carriers and excipients. The crystallinity,
polymorphism, and amorphicity of α-lactose monohydrate
(Figure 7a), the only US Food and Drug Administration–
approved carrier for use in dry powder pharmaceutical ae-
rosols, have been analyzed and distinguished using Raman
spectroscopy.130-133 The molecular nature of salbutamol (al-
buterol) sulfate134 (Figure 5a) and salts crystallized from
Figure 5. Chemical structures and molecular modeling of various pulmonary β-agonist and anticholinergic drugs that have been
studied by Raman spectroscopy: (A) albuterol sulfate (short-acting β-agonist); (B) ipratropium bromide monohydrate (anticholinergic);
and (C) salmeterol xinafoate (long-acting β2-agonist).
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salbutamol base135 has been examined using Raman spec-
troscopy. Particle engineering techniques such as supercritical
fluid (SCF) technology, solution-enhanced dispersion with
supercritical fluids (SEDS), supercritical fluid extraction of
emulsions, and spray-drying are used often in intelligently
designing respirable dry powder particles, as described in
detail by Hickey and Mansour.117Figure 8 illustrates the gen-
eral phase diagram of an SCF, which is liquefied gas existing
as a single phase above its critical point, Tc, and possessing
desirable properties of both its liquid (L) state and its gaseous
(G) state.117 It was reported136 that SEDS-produced lysozyme
retained biological activity as a respirable solid particle while
exhibiting minor changes in its FT-Raman spectra.
Lysozyme has often been used as a robust model protein in
biotherapeutic drug delivery, including dry powder inhala-
tion aerosols for dry powder inhalers (DPIs) and aerosol
propellant systems for metered-dose inhalers (MDIs). Quinn
et al137,138 investigated the biomolecular structural confor-
mational stability of lysozyme (predominantly α-helical con-
formation) and deoxyribonuclease I (predominantly β-sheet
conformation) in the hydrofluoroalkane (HFA) propellants
(7.5% wt/wt) tetrafluoroethane (HFA 134a) and heptafluor-
opropane (HFA 227) at 25-C, using FT-Raman consisting
of an Nd3+:YAG laser at 1064 nm with a laser power of
500 mW for solids and 800 mW for suspensions. Following
actuation, both proteins maintained enzymatic activity at
85% and 90% for DNase I in HFA 227 and HFA 134a, re-
spectively, and at 94% and 91% for lysozyme in HFA 227
and HFA 134a, respectively.137 FT-Raman provided mo-
lecular information related to secondary structure. For lyso-
zyme structural stability in the solid state and as an aqueous
Figure 6. Chemical structures and molecular modeling of various pulmonary corticosteroid drugs that have been studied by Raman
spectroscopy: (A) fluticasone propionate; (B) budesonide; and (C) beclomethasone dipropionate.
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solution, no significant changes were observed in the C-C band
(~900 cm–1), the characteristic amide I band (1660 cm–1),
the amide III band between 1264 cm–1 and 1300 cm–1 that
characterized lysozyme’s α-helical structure, and the disulfide
band (~507 cm–1) that characterized a gauche-gauche-gauche
conformation.138 The strongest propellant marker peaks
were at 857 cm–1 and 839 cm–1 for HFA 227 and HFA 134a,
respectively. Lysozyme maintained its structure in these pro-
pellants, as indicated from the FT-Raman spectra collected
through glass vials, wherein the amide I band (1660 cm–1)
and C-C band (900 cm–1 and 930 cm–1) did not change
significantly. However, the amide III band exhibited a de-
crease in intensity, and the authors attributed this to the
effect of the local environment (aqueous vs nonaqueous pro-
pellant) on the peptide backbone conformation.
Raman spectroscopy was employed by Dem et al126 in
tracking crystallization in a droplet of mannitol (Figure 7c)
during spray-drying by monitoring polymorphism in situ.
The Raman instrument (Nd: YAG laser at 532 nm) was
equipped with an electrodynamic trap (at a controlled rel-
ative humidity and temperature) where a single solid particle
or droplet can be levitated in the center of the trap with a
785-nm laser. The aqueous mannitol droplets, which had a
Figure 7. Chemical structures and molecular modeling of carriers and excipients used in pulmonary aerosol inhalation delivery systems
that have been studied by Raman spectroscopy: (A) lactose monohydrate; (B) trehalose dihydrate; and (C) D-mannitol.
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diameter of 90 μm, were then charged prior to entering the
trap. Single-particle Raman spectroscopy distinguished be-
tween 3 mannitol polymorphic forms during droplet evap-
oration at various relative humidities and temperatures, and
a polymorphic phase diagram with boundary lines was
constructed.126
Dispersive Raman imaging was reported139 in determining
the particle size distribution of the commercially available
combination product MDI, Combivent, which simultaneously
delivers the pulmonary drugs ipratropium bromide (Figure 5b),
an anticholinergic, and albuterol sulfate (Figure 5a), a short-
acting β-agonist, in 1 actuation. The Raman peaks mon-
itored were at 985 cm–1 and 1014 cm–1 for albuterol sulfate
and ipratropium bromide, respectively, and the spectral range
of 960 to 1040 cm–1 was used in Raman imaging (68-mW
laser power and 100 objective) of particles following 1 ac-
tuation and propellant evaporation. The spatial resolution was
~250 nm. Raman imaging has found utility in the identifica-
tion of foreign particles in a dry powder inhalation product, as
reported by Kreher et al,125 in 3 size ranges. It was found that
complementary information on chemical composition was
obtained for most DPI particles by SEM/X-microanalysis
and Raman microprobe, and Raman-identified organics such
as carbohydrates, long-chain hydrocarbons, polyethylene, and
polyvinylacetal moieties in the DPI particles.125
Dispersive Raman chemical imaging has been successfully
used to determine the chemical identity and particle size dis-
tribution of active drug (eg, beclomethasone dipropionate,
as shown in Figure 6c) from among inactive compounds
(carboxymethylcellulose sodium, microcrystalline cellulose,
polysorbate 80, dextrose, phenylethyl alcohol, and benzalko-
nium chloride) in suspension-based aerosols and aqueous
suspension nasal sprays containing high-dose corticosteroid,
such as the commercially available nasal spray product Be-
conase AQ.140,141 Beconase AQ was used as the control, and
5 formulated aqueous nasal spray suspensions were used in
the blind study. Full Raman spectra were obtained for the
aqueous suspension containing corticosteroid and excipients,
and chemical imaging revealed the optimal characteristic
drug peak marker at 1662 cm–1 that clearly distinguished the
active drug from the excipients. Particle size and shape of
the drug was determined from Raman chemical imaging of
dry deposits following actuation deposition onto aluminum-
coated glass microscope slides.
It has been reported that red-excitation dispersive Raman
spectroscopy can be applied to quantify polymorphism and
amorphous content in a multicomponent dry powder formu-
lation consisting of spray-dried mixtures of salmon calcitonin
and mannitol142 and in the study of the physical stability of
these dry powder inhalation systems.143 This technique of
combining red diode laser excitation with dispersive Raman
spectroscopy provides enhanced signal-to-noise ratio, higher
sensitivity, and less sample heating compared with FT or
dispersive Raman spectroscopy.142 Combining a sensitive
Raman system with visible excitation provides an enhanced
signal-to-noise ratio, and the fluorescence background caused
by visible excitation is not a limitation (as it is for biological
applications) for pharmaceutical materials (excipients, bio-
polymers, proteins) owing to their high purity. These dry
powder aerosols were analyzed by a diode laser operating at a
wavelength of 669.85 nm, at a power of 250 mW, and with a
spectral bandwidth of 1 cm–1. The digital sensor was com-
posed of a cryogenically cooled CCD system. This parti-
cular Raman system was equipped with an aluminum cavity
(1-μL volume) for a 100 to 800 μg sample such that scat-
tered laser radiation could be reflected back into the powder
sample, leading to improved signal.
Raman spectroscopy has been used on not only dry powder
aerosols but also aqueous aerosol particles and propellant-
based aerosol systems. Stimulated Raman scattering has
been used to characterize aqueous aerosols by linear Raman
spectroscopy.144 Scanning near-IR Raman microscopy has
been successfully used to map aerosol particulate deposits
on the stages of an Anderson cascade impactor (ACI), as
shown in Figure 9, from a combination pressurized MDI
(pMDI), Ventide.145 ACI is the standard in vitro model of
aerosol deposition in the lungs. A thorough understand-
ing of the deposition profiles can be achieved through
physicochemical investigations into the molecular and sur-
face interactions occurring in the pulmonary inhalation ae-
rosol delivery system (stability, adhesion, agglomeration, etc)
as a function of particle size fractions based on the ACI
stage deposition profiles. Aerosol deposits on stages 3 and 5
Figure 8. Phase diagram depicting the SCF region, the 2-phase
equilibria (coexistence) boundary lines, the triple point, Tp, and
the critical point, Tc. The SCF region is above Tc where a single-
phase liquefied gas exists. SCF indicates supercritical fluid.
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following a single Ventide pMDI actuation were used in Raman
mapping. The Raman system used a high-performance near-
IR 785-nm laser, and 10 mW of total laser energy was di-
rected to the sample for a 30-second time scan from 1338 cm–1
to 1829 cm–1. Raman maps were 100  100 μm in area,
where Raman bands at 1610 cm–1 and 1662 cm–1 represented
salbutamol and budesonide dipropionate, respectively. It
was reported that these Raman bands for the drugs exhibited
minimal interference from the pMDI excipients. Good cor-
relation was reported between the Raman maps of the ACI
plate stages and chemical analysis of the stages. Raman
mapping of the stages confirmed that no new molecular
bond formation (indicative of chemical degradation) in the
2 drugs occurred, based on the absence of new peaks and
drug peak shifts. The authors reported that even though
oleic acid may be present as a thin film on the stages, it
could not be detected by Raman spectroscopy, presumably
because of its low concentration, which was lower than the
limit of detection.
In addition to Raman chemical imaging of combinationMDI
products containing an anticholinergic and a short-acting
β-agonist, combination inhaled products containing a long-
acting β2-agonist and a corticosteroid have been investi-
gated. Seretide MDI is a commercially available combination
MDI product delivering fluticasone propionate (Figure 6a), a
corticosteroid, and salmeterol xinafoate (Figure 5c), a long-
acting selective β2-agonist, in the treatment of asthma. Asthma
is a complex disease state that exhibits both bronchoconstric-
tion and airway inflammation.146 A long-standing interest in
pulmonary inhalation aerosol delivery in the treatment of
asthma is the clinical observation that combination prod-
ucts are more efficacious than separate administration of the
2 component drugs. Perhaps this may be a result of simul-
taneous codeposition of both drugs on a cell via a single
inhaler in a single actuation in the same inspiratory breath.
Moreover, codeposition may enhance synergistic drug effects.
In an effort to gain insight into this, Theophilus et al147 in-
vestigated the deposition per actuation from the commercial-
ly available combination and single MDI products Seretide
(50 μg fluticasone propionate and 25 μg salmeterol), Se-
revent (25 μg salmeterol), and Flixotide (50 μg fluticasone
propionate). Being an in vitro size model of the central air-
ways, Plate 4 of the ACI, having a size range of 2.1 to 3.3 μm,
was analyzed by Raman spectroscopy following MDI actua-
tion at a flow rate of 28.3 L/min. The Raman microscope
setup consisted of a 100 objective lens, a confocal hole
set at 65 μm, and a cooled CCD detector connected to a
785-nm diode laser operating at 500 mW of laser power,
which provided spatial resolution of ~3.2 μm. Raman chem-
ical imaging was done on a 128 128 μm area. The authors
showed from their Raman chemical images that the combi-
nation inhalation product delivered from a single device had
significantly greater codeposition of both drugs, which sug-
gested that the particles in the combination MDI are asso-
ciated until the particles are deposited.147 It was acknowledged
that while the ACI is an in vitro model of pulmonary depo-
sition, the differences observed in vitro would be expected
to be much greater in vivo.147 Propellant evaporation is a
rapid, dynamic, and complex interfacial process where the
Figure 9. Schematic of Raman mapping of pharmaceutical inhalation aerosols. USP indicates US Pharmacopeia.
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drug interaction with the propellant can have significant ef-
fects on final particle characteristics, including particle size,
morphology, and deposition behavior. This particularly per-
tains to 2-drug MDI systems where coassociation between
the 2 drugs can favorably occur within an aerosol propellant
system, as has been previously reported148 with salmeterol
and fluticasone, and was demonstrated by Raman chemical
imaging of codeposition.147
As we have recently reported, a comprehensive set of ana-
lytical techniques, including bulk and surface characteriza-
tion methods, are necessary in the molecular characterization
of microparticulate and nanoparticulate systems designed for
pulmonary dry powder aerosol inhalation delivery.117,128,129
The information on the molecular, surface, and interfacial
properties that Raman characterization can provide is par-
ticularly important in applications related to respirable phar-
maceutical powders, where understanding the molecular
nature of these solid surfaces can enable their manipulation
and tailoring for functionality at the nanometer level for tar-
geted pulmonary delivery and deposition. Raman spectroscopy
and chemical imaging are powerful analytical techniques, as
detailed in this review, as they provide valuable molecular
insight into a variety of biocolloidal self-assemblies and drug
delivery systems, including inhalation aerosol drug delivery
systems. Future Raman spectroscopy and chemical imaging
investigations on pharmaceutical aerosols, particularly dry
powder aerosol inhalation delivery systems, should examine
the effects of temperature and relative humidity on hygro-
scopic particulate growth and in vitro aerosol performance,
which are then correlated with phase transformations and in
vitro deposition. Additionally, in vitro and in vivo Raman
chemical imaging of microparticulate and nanoparticulate
interactions with various living pulmonary epithelial cell
types and pulmonary immune cells will provide valuable and
needed biophysical insight into particulate uptake by living
pulmonary cells and transport in the lungs. Moreover, Raman
imaging in pulmonary medicine will enable a novel com-
bination of molecular insight and noninvasive imaging ca-
pability that can molecularly characterize infected pulmonary
cells, cancerous pulmonary cells, pulmonary disease states,
and cellular delivery and disposition following pulmonary
inhalation aerosol delivery.
CONCLUSIONS
As presented in this review, Raman mapping of aerosols at
the micro- and nanometer level of resolution and correlation
with in vitro aerosol lung deposition is now achievable with
new, sophisticated, commercially available Raman micro-
spectroscopy techniques. As has been demonstrated here,
Raman chemical imaging has unique, noninvasive, and ver-
satile applications in systems of pharmaceutical interest, and
hence has vast potential for application in pulmonary inha-
lation aerosol research. Unique and important application
potentials for Raman chemical imaging include aerosol de-
position molecular profiling in the lungs and in specific in-
dividual pulmonary cells, and nondestructive chemical
imaging of pulmonary aerosol inhalation delivery of bio-
colloidal self-assemblies and biotherapeutics, both in vitro
and in vivo.
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